The FDA approved the quadruplet regimen on July 30 for induction and consolidation therapies in patients with newly diagnoses multiple myeloma who are eligible for autologous stem cell transplant.
January 27, 2026: The U.S. Food and Drug Administration (FDA) approved the quadruplet therapy daratamumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib, lenalidomide, and ...
A late-breaking abstract presented at the American Society of Hematology Annual Meeting and Exposition supports the addition of subcutaneous daratumumab to standard-of-care bortezomib, lenalidomide, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results